Rapport Therapeutics, Inc. (RAPP) Balance Sheet
As of 2026-06-30 (10-Q), Rapport Therapeutics, Inc. (RAPP) reported total assets of $459.0M, total liabilities of $36.1M and shareholders' equity of $422.9M, according to EquiReason's reading of its SEC filings. Cash and equivalents: $63.6M.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
RAPPRapport Therapeutics, Inc.Follow RAPP — free
—
Price chart with a free account
- Market cap
- 1.2B
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 5 Nov, in 12 days
| Line | FY2024 Dec 24 | FY2025 Dec 25 | Latest Jun 26 | Trend |
|---|---|---|---|---|
| Cash and equivalents | 56.8 | 52.6 | 63.6 | |
| Short-term investments | 248.5 | 437.9 | 372.5 | |
| Receivables | — | 0.0 | 0.3 | |
| Current assets | 309.8 | 498.6 | 446.9 | |
| Total assets | 314.9 | 512.4 | 459.0 | |
| Current liabilities | 8.8 | 19.0 | 28.4 | |
| Total liabilities | 9.5 | 27.8 | 36.1 | |
| Shareholders' equity | 305.4 | 484.7 | 422.9 |
USD millions · SEC XBRL
Rapport Therapeutics, Inc. — questions
- How much cash does Rapport Therapeutics, Inc. have?
- $63.6M in cash and cash equivalents as of 2026-06-30.
- What are Rapport Therapeutics, Inc.'s total assets?
- $459.0M as of 2026-06-30.
- What is Rapport Therapeutics, Inc.'s shareholders' equity?
- $422.9M as of 2026-06-30.
Every figure on this page comes from Rapport Therapeutics, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.